Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Treatment of Mild Gestational Diabetes With Glyburide Versus Placebo

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Brian Casey, University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier:
NCT00744965
First received: August 29, 2008
Last updated: January 25, 2017
Last verified: January 2017
  Purpose
This is a randomized prospective trial which addresses the question of whether use of an oral hypoglycemic agent as an adjunct to diet therapy in women with mild gestational diabetes will result in achieving euglycemia in a shorter period of time and, in turn, result in less frequent maternal and neonatal morbidities. This study is designed to test the hypothesis that in women with mild GDM, use of Glyburide in addition to diet and nutritional counseling lowers mean infant birth weight by 200 grams as compared with diet and nutritional counseling alone.

Condition Intervention Phase
Mild Gestational Diabetes
Drug: Glyburide
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator
Primary Purpose: Treatment
Official Title: A Randomized Controlled Clinical Trial of Treatment of Mild Gestational Diabetes With Glyburide Versus Placebo

Resource links provided by NLM:


Further study details as provided by University of Texas Southwestern Medical Center:

Primary Outcome Measures:
  • Fetal weight reduction of 200gm with Glyburide treatment [ Time Frame: Immediately after delivery of fetus ]

Secondary Outcome Measures:
  • Large for gestational age infants [ Time Frame: After delivery ]
  • Macrosomia [ Time Frame: After delivery ]
  • Neonatal Intensive Care Unit admissions [ Time Frame: Until hospital discharge ]
  • Rate of cesarean delivery [ Time Frame: After delivery ]
  • Risk of preeclampsia [ Time Frame: until hospital discharge ]
  • Time to achieve glycemic control [ Time Frame: after delivery ]
  • Need for insulin treatment [ Time Frame: after delivery ]

Enrollment: 395
Study Start Date: August 2008
Study Completion Date: January 2016
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Women with mild gestational diabetes will be started ADA diet and a low dose of Glyburide and their medication dosage will be titrated as necessary during the pregnancy to achieve glucose control.
Drug: Glyburide
Starting dosage is 2.5 mg once daily. This dose will be titrated as necessary during the pregnancy to achieve glycemic control.
Placebo Comparator: 2
Women with mild gestational diabetes will be started ADA diet and placebo.
Drug: Placebo
Sham dose adjustments of the placebo will be made.

  Eligibility

Ages Eligible for Study:   16 Years to 45 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • A glucose value of ≥140 mg/dl on a 50-gram oral glucose loading test by plasma at gestational age between 24 weeks 0 days and 27 weeks 6 days based on clinical information
  • An Abnormal 3-hour oral glucose tolerance test with a fasting glucose of ≤105 mg/dl
  • Gestational age of less than or equal to 28 weeks and 0 days at the time of consent/randomization
  • Singleton gestation

Exclusion Criteria:

  • Established pregestational diabetes
  • Abnormal gestational diabetes testing (≥140) prior to 24 weeks 0 days of gestation. Women who have a negative glucose loading test (<140mg/dl) before 24 weeks may still be considered for this study if they present again for glucose tolerance testing between 24 and 27 weeks.
  • Multiple gestations
  • Known major fetal anomaly or fetal demise
  • Any renal disease with serum creatinine of >1.0
  • Known liver disease such as hepatitis
  • Maternal or fetal conditions likely to require imminent or very preterm delivery such as preeclampsia, preterm premature rupture of the membranes, preterm labor, and intrauterine fetal growth restriction
  • Known hypersensitivity or allergic reaction to Glyburide
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00744965

Locations
United States, Texas
Parkland Memorial Hospital
Dallas, Texas, United States, 75235
Sponsors and Collaborators
University of Texas Southwestern Medical Center
  More Information

Publications:
Responsible Party: Brian Casey, Professor, University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier: NCT00744965     History of Changes
Obsolete Identifiers: NCT00942552
Other Study ID Numbers: 032011-086
042008-058 ( Other Identifier: UTexasSouthwestern )
Study First Received: August 29, 2008
Last Updated: January 25, 2017

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes, Gestational
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Pregnancy Complications
Glyburide
Hypoglycemic Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 25, 2017